Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 84 of 1,261
  1. US 12134642

    Antibodies binding to α7β1 integrin antibodies and compositions thereof

    Pliant Therapeutics, Inc. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  2. US 12134631

    Hydrophilic linkers for antibody drug conjugates

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  3. US 12133840

    Halogenated xanthene composition and method for treating hematologic cancers

    Provectus Pharmatech, Inc. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  4. US 12133856

    Multi-substituent psilocybin derivatives and methods of using

    Enveric Biosciences Canada Inc. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  5. US 12133924

    Compositions and methods for organ specific delivery of nucleic acids

    The Board of Regents of the University of Texas System · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  6. US 12133853

    Pyruvate kinase activators for use in treating blood disorders

    Agios Pharmaceuticals, Inc. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  7. US 12133849

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeutic

    Actinium Phamaceuticals, Inc. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  8. US 12134610

    Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof

    CRINETICS PHARMACEUTICALS, INC. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  9. US 12133914

    Hydrocortisone oral liquid formulations

    Eton Pharmaceuticals, Inc. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  10. US 12133884

    Methods of substituting pathogenic amino acids using programmable base editor systems

    Beam Therapeutics Inc. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  11. US 12134609

    Quinoline cGAS antagonist compounds

    The Board of Regents of the University of Texas System · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  12. WO 2024223388

    COMPLEXES CRISTALLINS ENTRE LA VELAGLIFLOZINE ET DES AGENTS DE FORMATION DE CO-CRISTAUX SÉLECTIONNÉS, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION POUR LA PRÉPARATION DE MÉDICAMENTS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Oct 31, 2024 · Expires Oct 26, 2044

    granted
  13. US 12127536

    Humanized M-CSF mice

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  14. US 12128015

    APE/REF1 inhibitors for the treatment of cancer

    The Regents of the University of California · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  15. US 12128013

    Toxic aldehyde related diseases and treatment

    Aldeyra Therapeutics, Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  16. US 12128048

    Combination therapies using PRMT5 inhibitors for the treatment of cancer

    Mirati Therapeutics, Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  17. US 12128044

    Fused tricyclic compounds and uses thereof in medicine

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  18. US 12128034

    Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof

    Iterum Therapeutics International Limited · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  19. US 12128058

    Multi-substituent psilocybin derivatives and methods of using

    Enveric Biosciences Canada Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  20. US 12128090

    Methods of prophylactic treatment using recombinant VWF (rVWF)

    Takeda Pharmaceutical Company Limited · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  21. US 12128033

    Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine

    Neurocrine Biosciences, Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  22. US 12128052

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  23. US 12129222

    Production of bitter principle derivatives

    Julius-Maximilians-Universitaet · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  24. US 12128122

    Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic

    Krystal Biotech, Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.